



# ImmuPharma

## Immupharma: The Life Sciences Division's Dr Malik says shares are 'oversold' reiterating BUY rating

The Life Sciences Division's Dr Navid Malik offers up his thoughts and outlook on **ImmuPharma PLC (LON:IMM)**. Malik examines the company's flagship drug Lupuzor - a treatment for the autoimmune disease Lupus.

